In a 43‑year‑old woman (56 kg, normal renal function) who stopped dexamethasone after being on insulin glargine (Lantus) 24 U at 4 pm, should the initial basal dose be 12 U or 14 U?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Reduce Lantus to 12 Units After Stopping Dexamethasone

After discontinuing dexamethasone, reduce the basal insulin glargine (Lantus) dose to 12 units, representing approximately 50% of the current 24-unit dose. This substantial reduction is critical to prevent hypoglycemia, as insulin requirements decline rapidly once glucocorticoid therapy is stopped 1.

Rationale for 50% Dose Reduction

The evidence strongly supports aggressive dose reduction when dexamethasone is discontinued:

  • Guideline recommendation: Insulin requirements can decline rapidly after dexamethasone is stopped, and insulin doses should be adjusted accordingly 1. The Lancet guideline explicitly warns about this rapid decline in insulin needs.

  • Starting point calculation: For this 56 kg patient, if we calculate backward from the 24 units she was receiving:

    • Her baseline insulin needs (without dexamethasone) would be approximately 0.2-0.3 units/kg = 11-17 units
    • The FDA label recommends 0.2 units/kg for type 2 diabetes patients not currently on insulin 2
    • At 56 kg: 0.2 × 56 = 11.2 units, which rounds to approximately 12 units
  • Why not 14 units: The 14-unit option represents only a 42% reduction, which is insufficient given the rapid decline in glucocorticoid-induced insulin resistance. This conservative approach risks persistent hyperglycemia initially but more importantly fails to account for the precipitous drop in insulin requirements over 24-48 hours.

Conversion Guidance from FDA Label

The FDA label for Lantus provides specific conversion guidance that supports the 50% reduction approach 2:

  • When transferring from twice-daily NPH to once-daily Lantus, use 80% of the total NPH dose
  • This principle of dose reduction during insulin transitions applies here, though the dexamethasone discontinuation requires even more aggressive reduction

Monitoring Strategy

After initiating 12 units:

  • Check fasting blood glucose daily for the first 3-5 days
  • Titrate upward by 2 units every 3 days if fasting glucose remains >7 mmol/L (126 mg/dL) without hypoglycemia 3
  • Watch for hypoglycemia closely in the first 48 hours, as this is when glucocorticoid effects dissipate most rapidly
  • Target fasting glucose of 5.5-7.0 mmol/L (100-126 mg/dL)

Common Pitfalls to Avoid

Critical error: Reducing the dose too conservatively (e.g., only to 14 units or 20 units) based on fear of hyperglycemia. The evidence shows that dexamethasone-induced insulin resistance resolves quickly 1, and maintaining high basal insulin doses after steroid discontinuation leads to severe hypoglycemia risk, particularly nocturnal hypoglycemia.

Timing consideration: Administer the 12 units at the same time daily (continue the 4 pm timing if that was the established schedule) to maintain consistency 2.

References

Related Questions

If a patient received dexamethasone 4 mg at 8 am and insulin glargine (Lantus) 13 units at 2 pm today, and will not receive dexamethasone tomorrow, what should the insulin glargine dose be for the next day?
How should the insulin regimen be adjusted for a patient with a recent A1C of 10% who is currently on sliding‑scale insulin and insulin glargine (100 U/mL)?
In a 67-year-old female weighing 75 kg who received dexamethasone 10 mg 48 hours ago, has poor oral intake, and was given insulin glargine (Lantus) 36 units at 1500 h with a current insulin‑to‑carbohydrate ratio of 1 unit per 7 g carbohydrate and an insulin sensitivity factor of 1 unit per 25 mg/dL, what should the basal insulin dose, insulin sensitivity factor, and insulin‑to‑carbohydrate ratio be adjusted to?
Should I decrease my insulin glargine (Lantus) dose, currently 22 units, given a blood glucose of 219 mg/dL at 2 am and 152 mg/dL at 7 am?
For a 43-year-old female weighing 56 kg with normal renal function who received dexamethasone 4 mg yesterday and has glucose readings of 296, 396, 304, 373, and 251 mg/dL, currently using an insulin‑sensitivity factor of 25 mg/dL per unit, an insulin‑to‑carbohydrate ratio of 10 g per unit, and basal insulin (insulin glargine, Lantus) 24 U at 4 pm, what should the insulin‑sensitivity factor, insulin‑to‑carbohydrate ratio, and basal insulin dose be now that dexamethasone will be discontinued today?
How can I use knowledge, information, and data to develop a data‑driven care plan for an adult with secondary lymphedema after cancer surgery or radiation?
What are the clinical manifestations of protein S deficiency?
In a 2‑year‑and‑6‑month‑old girl with mucus‑containing stool yesterday and current vomiting with phlegm, what diagnosis should be suspected—viral gastroenteritis or another condition?
What are the causes of elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase, and how should the workup be approached?
In a 48-year-old male with severe constipation while taking dapagliflozin, metformin, glimepiride, and teneligliptin, how should the offending anti-diabetic medication be tapered or discontinued?
What is the appropriate management for a subdural hematoma with perifocal edema causing a 3 mm shift of the lateral ventricle?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.